Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solabegron in women with overactive bladder
NCT03594058Phase 2Completed
- Sponsor
- Velicept Therapeutics
- Start
- Jul 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Solabegron in overactive bladder (OAB), sponsored by Velicept Therapeutics. Started Jul 2018; status: completed.
02
Drugs
Solabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT03594058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03594058.